


THU0298 INITIAL MANIFESTATIONS AND OUTCOME OF PATIENTS WITH INCOMPLETE BEHÇET’S SYNDROME

Sinem Nihal Esatoğlu1, Seyda Bilgın2, Cem Sulu3, Vedat Hamuryudan3, Zekayi Kutlubay1, Serdal Uğurú1, Emire Seyahi2, Melike Melikoglu2, İzzet Fresko3, Sebahattin Yurdakul1, Hasan Yazić1, Gulen Hatemi4, Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey; 2Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Istanbul, Turkey; 3Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Rheumatology, Istanbul, Turkey; 4Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Dermatology, Istanbul, Turkey

Background: Behçet’s syndrome (BS) has a heterogeneous expression involving many organ systems and is diagnosed by recognizing the coexisting manifestations. Several patients initially have few of these manifestations and do not fulfill the International Study Group (ISG) criteria. When these are major organ manifestations, failure to recognize BS and treat promptly may lead to permanent damage in these organs.

Objectives: The aim of this study is to highlight the magnitude of this problem by surveying the frequency, presentation patterns and outcome of patients who did not fulfill ISG criteria when they presented to our clinic, but were followed and treated for manifestations strongly suggesting BS.

Methods: We conducted a retrospective chart review of all BS patients who were registered between 2003 and 2008. Among these 2385 patients, 199 (8%) BS patients who did not fulfill ISG criteria at their initial visit were included in this study. Patients were called and a standard form was used for collecting demographic characteristics, BS manifestations at initial visit and during follow-up and treatment.

Results: Among the 199 patients (M:W: 90/109, mean age: 34 ± 11 years) who did not fulfill ISG criteria when they presented to our clinic, 70 (35%) had major organ involvement. The types of major organ involvement that led to a diagnosis of BS at initial visit despite not fulfilling ISG criteria were eye involvement in 37, vascular involvement in 29 (venous thrombosis in 22, arterial aneurysm in 7), nervous system involvement in 3 and gastrointestinal (GI) involvement in 1 patient. Thirty-five patients (18%) had a family history of BS.

Of 199 patients, 167 had at least one more visit with a median follow-up of 11 years (IQR: 7-12). We were able to contact 116 of these patients and saw that 52 had fulfilled ISG criteria in the meantime. Among the 51 patients that we were not able to contact, 17 had fulfilled criteria while they were being followed in our clinic. Thus, a total of 70 (42%) patients fulfilled ISG criteria after a median follow-up of 1.5 years (IQR: 1-4.25). All but 2 patients who developed eye involvement during the follow-up had fulfilled ISG criteria with a new mucocutaneous manifestation. After a median follow-up of 4 years (IQR: 1-7), 23 (14%) patients had developed at least one non-criteria BS manifestation, including vascular involvement in 10, arthritis in 13, neurologic involvement in 2 patients and GI involvement in 1 patient.

Among the 81 patients who developed at least one new manifestation, 16 (20%) were under immunosuppressive or interferon-alpha treatment at the time they developed their new manifestation. The remaining 65 patients, 199 (8%) BS patients who did not fulfill ISG criteria when they presented to our clinic, but were followed and treated for manifestations strongly suggesting BS.

Disclosure of Interests: Sinem Nihal Esatoğlu: None declared, Seyda Bilgın: None declared, Cem Sulu: None declared, Vedat Hamuryudan

Consultant for: Abbvie, Amgen, BMS, Jansen, MSD, Pfizer, UCB, Speakers bureau: Abbvie, Amgen, BMS, Jansen, MSD, Pfizer, UCB, Zekayi Kutlubay: None declared, Serdal Uğurú: None declared, Emire Seyahi: None declared, Melike Melikoglu: None declared, İzzet Fresko: None declared, Sebahattin Yurdakul: None declared, Hasan Yazić: None declared, Gulen Hatemi Consultant for: Abbvie, Amgen, BMS, Jansen, MSD, Pfizer, UCB, Speakers bureau: Abbvie, Amgen, BMS, Jansen, MSD, Pfizer, UCB, DOI: 10.1136/annrheumdis-2019-eular.4827

THU0299 PATIENT GLOBAL ASSESSMENT OF DISEASE ACTIVITY IN BEHÇET’S SYNDROME: A MULTICENTER STUDY

Alberto Flórez1, Matteo Piga1, Gerard Espinosa2, Nikolaos Koukdas2, Andrea Lo Monaco3, Giuseppe Lopalco3, Ida Orlando3, Vittorio Piri4, Emestina Santos5,6, Luisa Serpa Pinto6,7, George Bertisa2, Luca Cantarini2, Alberto Caua2, Ricard Cervera2, João Correia8, Marcello Govoni9, Fiorenzo Iannone5, Ana Martins Da Silva5,6, Piergiorgio Neri1,10,11 Carbon Vasconcelos3,4, Alessandro Mathieu1,1 University of Cagliari, Rheumatology, Monserrato, Italy, 2University of Barcelona, Department of Autoimmune Diseases, Barcelona, Catalonia, Spain, 3University of Crete, Rheumatology, Clinical Immunology and Allergy, Heraklion, Greece, 4University of Ferrara, Rheumatology, Ferrara, Italy, 5University of Bari, Rheumatology, Bari, Italy, 6University of Siena, Rheumatology, Siena, Italy, 7Università Politecnica delle Marche, Ophthalmology, Ancona, Italy, 8Centro Hospitalar do Porto/Hospital de Santo António, Neurology, Portugal, Porto, 9University of Porto, UMB Abal Salazar Biomedical Sciences Institute, Porto, Portugal, 10Hospital Santo Antonio Centro Hospitalar do Porto, Unidade de Imunologia Clínica, Unidade de Imunologia Clínica, Porto, Portugal, 11 Cleveland Clinic Abu Dhabi, Eye Institute, Abu Dhabi, United Arab Emirates

Background: Disease activity evaluation is mandatory according to the OMERACT Core Set of Domains for Behçet’s Syndrome (BS). Poor data are available on Patient (PtGA) and physician (PGA) global assessment of disease activity in BS.

Objectives: To assess PtGA performance in patients with BS and how different disease manifestations influence the patient and physician’s perception of disease activity.

Methods: A multicenter cross-sectional cohort of consecutive BS patients was enrolled. Disease activity was evaluated by PtGA, PGA and the Behçet’s disease current activity form (BDCF). PtGA and PGA were assessed through a single question (“How active was BS during the last week?”) in a 10-cm visual analog scale. Health related quality of life (HRQoL) perception was evaluated by the Physical Component Summary (PCS) and the Mental Component summary (MCS) of the SF36v2 questionnaire. Correlation between PtGA, PGA, BDCF and between them and SF36v2 component summaries was assessed through the Spearman’s correlation coefficient (rho). Two separated multiple regression models were built to measure the independent effect of β (regression) of each active clinical manifestation on PtGA and PGA.

Results: Overall, 226 BS patients from 5 Mediterranean Countries were enrolled. Out of them, 111 (49.1%) were males and the median (IQR) age and disease duration were 46.9 (35.6-55.2) and 11.7 (5.9-20.8) years, respectively. The median (IQR) value of PtGA, PGA and BDCF were 2.0 (3.0-5.0), 1.0 (0.0-3.0) and 3.0 (0.0-5.0), respectively. PtGA significantly correlated (Figure) with both PGA (rho 0.759. p < 0.001) and BDCF (rho 0.523. p < 0.001), in support of its construct validity. PtGA scores were significantly higher than PGA with a mean (SD) difference of 0.8 (1.8), suggesting a different weighing of disease activity between patients and physicians. Indeed, PtGA and PGA were differently influenced by active clinical manifestations (Table). PtGA was mainly dependent on active mucocutaneous (β 0.243), gastrointestinal (β 0.216) and ocular (β 0.209) involvement whereas a major effect of ocular manifestations was observed in PGA (β 0.378). PtGA was correlated with worse HRQoL perception measured by PCS (rho -0.476. p < 0.001) and MCS (rho -0.451. p < 0.001). Conclusion: PtGA seems to be a valid outcome measure in BS and should be considered as a separate outcome measure or better be included in composite index for overall disease activity evaluation.

Abstract THU299 – Table 1.

PtGA          PGA

Abstract THU0299 – Impact of Vascular Ultrasound on Evaluation of Giant Cell Arteritis Among 503 Patients in an Academic Medical Center

Julia Ford1, Michael DiPioro1, William Docken1, Piotr Sobieszczyk2, Sara Tedesch2, Alberto Floris: None declared, Matteo Piga: None declared, Andrea Lo Monaco: None declared, Giuseppe Lopalo, Speakers bureau: SOBI, BMS, Ida Orlando: None declared, Vittoria Pirani: None declared, Ernestina Santos: None declared, Luisa Serpa Pinto: None declared, George Bertsias: None declared, Luca Cantarini: None declared, Andrea Lo Monaco: None declared, Giuseppe Lopalo, Disclosure of Interests: Alberto Floris: None declared, Matteo Piga: None declared, Andrea Lo Monaco: None declared, Giuseppe Lopalo, Speakers bureau: SOBI, BMS, Ida Orlando: None declared, Vittoria Pirani: None declared, Ernestina Santos: None declared, Luisa Serpa Pinto: None declared, George Bertsias: None declared, Luca Cantarini: None declared, Andrea Lo Monaco: None declared, Giuseppe Lopalo, Consultants for: F Iannone has received consultancy fees and/or speaker honoraria from Pfizer, AbbVie, MSD, BMS, Novartis, Lilly, UCB outside this work, Ana Martins da Silva: None declared, Piergiorgio Neri: None declared, Carlos Vasconcelos: None declared, Alessandro Mathieu: None declared.

Disclosure of Interests: Alberto Floris: None declared, Matteo Piga: None declared, Andrea Lo Monaco: None declared, Giuseppe Lopalo, Speakers bureau: SOBI, BMS, Ida Orlando: None declared, Vittoria Pirani: None declared, Ernestina Santos: None declared, Luisa Serpa Pinto: None declared, George Bertsias: None declared, Luca Cantarini: None declared, Andrea Lo Monaco: None declared, Giuseppe Lopalo, Consultants for: F Iannone has received consultancy fees and/or speaker honoraria from Pfizer, AbbVie, MSD, BMS, Novartis, Lilly, UCB outside this work, Ana Martins da Silva: None declared, Piergiorgio Neri: None declared, Carlos Vasconcelos: None declared, Alessandro Mathieu: None declared.

EVALUATION OF GIANT CELL ARTERITIS AMONG 503 PATIENTS IN AN ACADEMIC MEDICAL CENTER

Julia Ford1, Michael DiPioro1, William Docken1, Piotr Sobieszczyk2, Sara Tedesch2, 1Brigham and Women’s Hospital, Department of Medicine, Division of Rheumatology, Allergy and Immunology, Boston, United States of America; 2Brigham and Women’s Hospital, Department of Medicine, Division of Cardiovascular Medicine, Boston, United States of America

Background: As vascular ultrasound (VUS) is increasingly used in evaluation of giant cell arteritis (GCA), its impact on clinical care is of great interest.

Objective: To describe utilization of VUS in GCA evaluation at a large academic medical center and investigate impact of VUS on clinical impression.

Methods: We performed a retrospective cohort study of patients who underwent VUS at a single center in Boston, 2013-2017, to evaluate suspected or known GCA. Trained cardiovascular ultrasound technicians used a standardized protocol to image the temporal, carotid, subclavian, and axillary arteries for presence of hypoechoic circumferential wall thickening (halo sign), hyperechoic wall thickening, stenosis, and occlusion. VUS images were interpreted by trained cardiovascular medicine physicians as consistent with acute arteritis ("acute"), no evidence of arteritis ("none"), or hyperechoic wall thickening without halo sign ("hyperechoic"). Diagnostic laboratory, medication, pathology and clinical data including the treating physician’s clinical suspicion for GCA pre- and post-VUS were obtained by electronic medical record review. Fisher’s exact test and Wilcoxon rank-sum test were compared baseline characteristics among patients with VUS positive for acute arteritis ("acute") vs. negative for acute arteritis ("none" or "hyperechoic"). We compared the treating physician’s pre- and post-VUS clinical suspicion for GCA among patients with no history of GCA or aortitis.

Results: We identified 503 patients with median age 70.4 years; 69.0% were female and 87.5% White. VUS interpretation was acute in 48 patients (9.5%), none in 427 (84.9%), and hyperechoic in 28 (5.6%). Baseline characteristics are presented in Table 1. Weight loss, cranial symptoms, higher ESR, and steroid use were more common in patients with VUS positive for acute arteritis. Change in the treating physician’s clinical suspicion for GCA is shown in Figure 1. VUS positive for acute arteritis increased suspicion for GCA in 26/35 (74%) cases, and VUS negative for acute arteritis lowered suspicion for GCA in 303/396 (77%). Of 110 patients with a temporal artery biopsy after VUS, 16 (14.6%) biopsies showed active arteritis; 11 of these were in patients with VUS negative for acute arteritis.

Conclusion: VUS results changed the clinical suspicion for GCA in approximately 75% of patients in this large cohort.

Table 1. Characteristics at the time of VUS

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>VUS Positive (n=48)</th>
<th>VUS Negative (n=355)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years</td>
<td>70.4 (62.7, 77.5)</td>
<td>73.2 (65.8, 79.7)</td>
<td>0.046</td>
</tr>
<tr>
<td>History of GCA or aortitis</td>
<td>14.3 (7.3, 21.3)</td>
<td>27.1 (13.0, 40.0)</td>
<td>0.02</td>
</tr>
<tr>
<td>History of PMR</td>
<td>31.2 (20.9, 41.9)</td>
<td>22.9 (13.2, 32.1)</td>
<td>NS</td>
</tr>
<tr>
<td>Weight loss</td>
<td>51.3 (40.4, 60.3)</td>
<td>69.0 (50.3, 79.3)</td>
<td>NS</td>
</tr>
<tr>
<td>Fatigue</td>
<td>36.2 (45.8, 35.2)</td>
<td>13.0 (5.9, 21.1)</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Jaw claudication</td>
<td>10.9 (3.3, 33.3)</td>
<td>8.6 (0.0, 18.6)</td>
<td>NS</td>
</tr>
<tr>
<td>Scalp tenderness</td>
<td>17.1 (7.5, 35.0)</td>
<td>15.0 (0.0, 30.0)</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>TA tenderness/decresed TA pulse</td>
<td>14.5 (7.0, 29.2)</td>
<td>13.0 (0.0, 29.2)</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Transient vision loss</td>
<td>7.8 (4.0, 10.4)</td>
<td>7.5 (0.0, 15.0)</td>
<td>NS</td>
</tr>
<tr>
<td>Permanent vision loss</td>
<td>3.0 (0.0, 6.3)</td>
<td>2.6 (0.0, 7.8)</td>
<td>NS</td>
</tr>
<tr>
<td>CRP*, mg/L</td>
<td>15.7 (3.1, 76.0)</td>
<td>36.3 (8.1, 81.9)</td>
<td>0.003</td>
</tr>
<tr>
<td>ESR*, mm/h</td>
<td>40 (18, 83)</td>
<td>67 (30, 95)</td>
<td>&lt;0.01</td>
</tr>
</tbody>
</table>

*Presented as median (interquartile range). CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; GCA: giant cell arteritis; PMR: polymyalgia rheumatica; TA: temporal artery; VUS: vascular ultrasound. NS: not significant.

**p<0.046